|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pre-operative factors that can predict neoplastic polypoid lesions of the gallbladder显示文摘AIM:To investigate the preoperative factors that can predict neoplastic polypoid lesions of the gallbladder(PLGs) as well as malignant PLGs.METHODS:A retrospective analysis was conducted on the 210 consecutively enrolled patients who underwent cholecystectomy due to a PLG larger than 10 mm,as was determined by preoperative trans-abdominal ultrasonography or endoscopic ultrasonography.We ana-lyzed the medical,laboratory,radiologic data and the pathologic results.RESULTS:In 210 cases,146 had non-neoplastic polyps(69.5%) and 64 cases were neoplastic polyps(30.5%).An older age(≥ 65 years),the presence of diabetes mellitus(DM) and the size of polyp(≥ 15 mm) were revealed to be independent predictive variables for neoplastic polyps with odd ratios(OR) of 2.27(P = 0.044),2.64(P = 0.021) and 4.94(P < 0.01),respectively.Among the neoplastic PLGs,an older age(≥ 65 years),the presence of DM and polyp size(≥ 15 mm) were associated with malignancy with ORs of 4.97(P = 0.005),6.13(P = 0.001) and 20.55(P < 0.001),respectively.CONCLUSION:Among patients with PLGs larger than 10 mm in size,higher risk groups such as elderly patients more than 65 years old,those with DM or a large polyp size(≥ 15 mm) should be managed by cholecystectomy. | Byung Hyo Cha Jin-Hyeok Hwang Sang Hyub Lee Jang Eon Kim Jai Young Cho Haeryoung Kim So Yeon Kim | 2011 | World Journal of Gastroenterology2011，17，17： | 27 |
| 2 | Biliary drainage for obstructive jaundice caused by unresectable hepatocellular carcinoma: the endoscopic versus percutaneous approach显示文摘BACKGROUND: For palliative treatment of the obstructive jaundice associated with unresectable hepatocellular carcinoma (HCC), percutaneous transhepatic biliary drainage (PTBD) or endoscopic retrograde biliary drainage (ERBD) has been performed. PTBD is preferred as an initial procedure. Little is known about the better option for patients with obstructive jaundice caused by unresectable HCC. METHODS: Sixty patients who had received ERBD or PTBD for the palliative treatment of obstructive jaundice caused by unresectable HCC between January 2006 and May 2010 were included in this retrospective study. Successful drainage, drainage patency, and the overall survival of patients were evaluated. RESULTS: Univariate analysis revealed that the overall frequency of successful drainage was higher in the ERBD group (22/29, 75.9%) than in the PTBD group (15/31, 48.4%) (P=0.029); but multivariate analysis showed marginal significance (P=0.057). The duration of drainage patency was longer in the ERBD group than in the PTBD group (82 vs 37 days, respectively, P=0.020). Regardless of what procedure was performed, the median survival time of patients who had a successful drainage was much longer than that of the patients who did not have a successful drainage (143 vs 38 days, respectively, P<0.001).CONCLUSION: Besides PTBD, ERBD may be used as the initial treatment option to improve obstructive jaundice in patients with unresectable HCC if there is a longer duration of drainage patency after a successful drainage. | Jongkyoung Choi Ji Kon Ryu Sang Hyub Lee Dong-Won Ahn Jin-Hyeok Hwang Yong-Tae Kim Yong Bum Yoon Joon Koo Han | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，6： | 17 |
| 3 | Optimal biliary drainage for inoperable Klatskin's tumor based on Bismuth type显示文摘AIM: To investigate differences in the effects of biliary drainage procedures in patients with inoperable Klatskin’s tumor based on Bismuth type, considering endoscopic retrograde biliary drainage (ERBD), external percutaneous transhepatic biliary drainage (EPTBD) and internal biliary stenting via the PTBD tract (IPTBD). METHODS: The initial success rate, cumulative patency rate, and complication rate were compared retrospectively, according to the Bismuth type and ERBD, EPTBD, and IPTBD. Patency was defined as the duration for adequate initial bile drainage or to the point of the patient’s death associated with inadequate drainage. RESULTS: One hundred thirty-four patients (93 men, 41 women; 21 Bismuth type Ⅱ, 47 Ⅲ, 66 Ⅳ; 34 ERBD, 66 EPTBD, 34 IPTBD) were recruited. There were no differences in demographics among the groups. Adequate initial relief of jaundice was achieved in 91% of patients without a significant difference in the results among different procedures or Bismuth types. The cumulative patency rates for ERBD and IPTBD were better than those for EPTBD with Bismuth type Ⅲ. IPTBD provided an excellent response for Bismuth type Ⅳ. However, there was no difference in the patency rate among drainage procedures for Bismuth type Ⅱ. Procedure-related cholangitis occurred less frequently with EPTBD than with ERBD and IPTBD. CONCLUSION: ERBD is recommended as the first- line drainage procedure for the palliation of jaundice in patients with inoperable Klatskin’s tumor of Bismuth type Ⅱ or Ⅲ, but IPTBD is the best option for Bismuth type Ⅳ. | Sang Hyub Lee Joo Kyung Park Won Jae Yoon Jun Kyu Lee Ji Kon Ryu Yong Bum Yoon Yong-Tae Kim | 2007 | World Journal of Gastroenterology2007，13，29： | 17 |
| 4 | Endoscopic submucosal dissection for early gastric cancer with undifferentiated-type histology:A meta-analysis显示文摘AIM: To evaluate the efficacy and safety of endoscopicsubmucosal dissection(ESD) for early gastric cancer(EGC) with undifferentiated-type histology.METHODS: A systematic literature review was conducted using the core databases. Complete resection,curative resection, en bloc resection, recurrence and adverse event rate were extracted and analyzed. A random effect model was applied. The methodological quality of the enrolled studies was assessed using the Newcastle-Ottawa Scale. Publication bias was evaluated using a funnel plot, the trim and fill method, Egger's test,and a rank correlation test.RESULTS: Fourteen retrospective studies between2009 and 2014 were identified(972 EGC lesions with undifferentiated-type histology). The total en bloc and complete resection rates were estimated as92.1%(95%CI: 87.4%-95.2%) and 77.5%(95%CI:69.3%-84%), respectively. The total curative resection rate was 61.4%(95%CI: 44.5%-75.9%). The overall recurrence rate was 7.6%(95%CI: 3.4%-16%).Limited to histologically diagnosed expanded-criteria lesions, the en bloc and complete resection rates were91.2% and 85.6%, respectively. The curative resection rate was 79.8%.CONCLUSION: In this analysis, ESD is a technically feasible treatment modality for EGC with undifferentiatedtype histology. Long-term studies are needed to confirm these therapeutic outcomes. | Chang Seok Bang Gwang Ho Baik In Soo Shin Jing Bong Kim Ki Tae Suk Jai Hoon Yoon Yeon Soo Kim Dong Joon Kim Woon Geon Shin Kyung Ho Kim Hak Yang Kim Hyun Lim Ho Seok Kang Jong Hyeok Kim Jin Bae Kim Sung Won Jung Sea Hyub Kae Hyun Joo Jang Min Ho Choi | 2015 | World Journal of Gastroenterology2015，21，19： | 14 |
| 5 | Role of surgical resection for multiple hepatocellular carcinomas显示文摘AIM:To clarify the role of surgical resection for multiple hepatocellular carcinomas(HCCs)compared to transarterial chemoembolization(TACE)and liver transplantation(LT). METHODS:Among the HCC patients who were managed at Yonsei University Health System between January 2003 and December 2008,160 patients who met the following criteria were retrospectively enrolled:(1) two or three radiologically diagnosed HCCs;(2)no radiologic vascular invasion;(3)Child-Pugh class A;(4) main tumor smaller than 5 cm in diameter;and(5) platelet count greater than 50 000/mm3.Long-term outcomes were compared among the following three treatment modalities:surgical resection or combined radiofrequency ablation(RFA)(n=36),TACE(n=107), and LT(n=17).The survival curves were computed using the Kaplan-Meier method and compared with a log-rank test.To identify the patients who gained a survival benefit from surgical resection,we also investigated prognostic factors for survival following surgical resection.Multivariate analyses of the prognostic factors for survival were performed using the Cox proportional hazard model. RESULTS:The overall survival(OS)rate was significantly higher in the surgical resection group than in the TACE group(48.1%vs 28.9%at 5 years,P<0.005). LT had the best OS rate,which was better than that of the surgical resection group,although the difference was not statistically significant(80.2%vs 48.1%at 5 years,P=0.447).The disease-free survival rates were also significantly higher in the LT group than in the surgical resection group(88.2%vs 11.2%at 5 years, P<0.001).Liver cirrhosis was the only significant prognostic factor for poor OS after surgical resection. Clinical liver cirrhosis rates were 55.6%(20/36)in the resection group and 93.5%(100/107)in the TACE group.There were 19 major and 17 minor resections. En bloc resection was performed in 23 patients,multisite resection was performed in 5 patients,and combined resection with RFA was performed in 8 patients. In the TACE group,only 34 patients(31.8%)were recorded as having complete remission after primary TACE.Seventy-two patients(67.3%)were retreated with repeated TACE combined with other therapies. In patients who underwent surgical resection,the 16 patients who did not have cirrhosis had higher 5-year OS and disease-free survival rates than the 20 patients who had cirrhosis(80.8%vs 25.5%5-year OS rate, P=0.006;22.2%vs 0%5-year disease-free survival rate,P=0.048).Surgical resection in the 20 patients who had cirrhosis did not provide any survival benefit when compared with TACE(25.5%vs 24.7%5-year OS rate,P=0.225).Twenty-nine of the 36 patients who underwent surgical resection experienced recur-rence.Of the patients with cirrhosis,80%(16/20) were within the Milan criteria at the time of recurrence CONCLUSION:Among patients with two or three HCCs, no radiologic vascular invasion,and tumor diameters≤ 5 cm,surgical resection is recommended only in those without cirrhosis. | Sung Hoon Choi Gi Hong Choi Seung Up Kim Jun Yong Park Dong Jin Joo Man Ki Ju Myoung Soo Kim Jin Sub Choi Kwang Hyub Han Soon Il Kim | 2013 | World Journal of Gastroenterology2013，19，3： | 12 |
| 6 | Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma显示文摘 | Masao Omata Laurentius A. Lesmana Ryosuke Tateishi Pei-Jer Chen Shi-Ming Lin Haruhiko Yoshida Masatoshi Kudo Jeong Min Lee Byung Ihn Choi Ronnie T. P. Poon Shuichiro Shiina Ann Lii Cheng Ji-Dong Jia Shuntaro Obi Kwang Hyub Han Wasim Jafri Pierce Chow Seng | 2010 | Hepatology International2010，，2： | 11 |
| 7 | Risk factors of organ failure in cholangitis with bacteriobilia显示文摘AIM: To identify the risk factors for organ failure(OF) in cholangitis with bacteriobilia.METHODS: This study included 182 patients with acute cholangitis who underwent percutaneous transhepatic biliary drainage between January 2005 and April 2013. We conducted a retrospective analysis of comprehensive clinical and laboratory data.RESULTS: There were 24 cases(13.2%) of OF and five deaths(2.7%). Bile culture was positive for microbial growth in 130 out of 138(94.2%) patients. In multivariate analysis of 130 patients with positivebile cultures, significant predictive factors for OF were the presence of extended-spectrum beta-lactamase(ESBL) organisms in blood cultures, pre-existing renal dysfunction, and choledocholithiasis as an etiology, with odds ratios of 15.376, 6.319, and 3.573, respectively. We developed a scoring system with a regression coefficient of each significant variable. The OF score was calculated using the following equation:(2.7 × ESBL organisms in blood cultures) +(1.8 × pre-existing renal dysfunction) +(1.3 × choledocholithiasis). This scoring system for predicting OF was highly specific(99.1%) and had a positive predictive value of 86.2%.CONCLUSION: ESBL organisms in blood cultures, preexisting renal dysfunction, and choledocholithiasis are risk factors for OF in cholangitis with bacteriobilia. The OF scoring system may aid clinicians to identify a poor prognosis group. | Jae Min Lee Sang Hyub Lee Kwang Hyun Chung Jin Myung Park Ban Seok Lee Woo Hyun Paik Joo Kyung Park Ji Kon Ryu Yong-Tae Kim | 2015 | World Journal of Gastroenterology2015，21，24： | 8 |
| 8 | Safety of endoscopic ultrasound-guided ethanol ablation for pancreatic cystic lesions: A single-center experience of 214 patients显示文摘Background:Endoscopic ultrasound-guided ethanol ablation(EUS-EA)for pancreatic cystic lesions(PCLs)has been used in recent years as a feasible treatment modality for low malignant probability PCLs or patients considered high-risk for surgery.The present study aimed to confirm the safety of EUS-EA and to find predictive factors for adverse event(AE).Methods:A retrospective review was performed from the prospectively maintained database of patients who underwent EUS-EA for PCLs from June 2006 to April 2018 at Seoul National University Hospital.The primary outcomes of the study were the rates of AEs and severe AEs by EUS-EA.The secondary outcome was the predictive factors of AEs including acute pancreatitis and abdominal pain.Results:A total of 214 patients were evaluated and the diagnoses of PCLs according to cystic fluid analysis and clinical features were as follows:serous cystic neoplasm(32.2%),mucinous cystic neoplasm(26.6%),branch duct type intraductal papillary mucinous neoplasm(BD-IPMN)(29.4%),and pseudocyst(11.7%).Three patients(1.4%)experienced severe AEs.Overall,AEs occurred in 71(33.2%)patients.BD-IPMN(OR:2.87;95%CI:1.05–7.84;P=0.040),multilocular cysts(OR:3.59;95%CI:1.09–11.85;P=0.036),suspected ethanol leakage during procedure(OR:10.68;95%CI:1.98–57.53;P=0.006),and sticky cystic fluid(OR:3.83;95%CI:1.20–12.24;P=0.024)were predictive factors for post-procedural acute pancreatitis.PCLs of uncinate process(OR:2.99;95%CI:1.22–7.35;P=0.017)and PCLs with exophytic portion(OR:3.70;95%CI:1.96–7.01;P<0.001)were predictive factors for post-procedural abdominal pain.Conclusions:EUS-EA is a safe procedure with a very low rate of severe AEs.It seems possible to predict the AEs according to the features of the procedure and PCLs. | Jin Ho Choi Sang Hyub Lee Young Hoon Choi Min Su You Bang-Sup Shin Woo Hyun Paik Ji Kon Ryu Yong-Tae Kim | 2019 | Hepatobiliary & Pancreatic Diseases International2019，18，6： | 6 |
| 9 | Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B显示文摘 | Ting‐Tsung Chang Yun‐Fan Liaw Shun‐Sheng Wu Eugene Schiff Kwang‐Hyub Han Ching‐Lung Lai Rifaat Safadi Samuel S. Lee Waldemar Halota Zachary Goodman Yun‐Chan Chi Hui Zhang Robert Hindes Uchenna Iloeje Suzanne Beebe Bruce Kreter | 2010 | Hepatology2010，，： | 4 |
| 10 | Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer显示文摘AIM:To evaluate the anti-tumor effect of clobenpropit,which is a specific H3 antagonist and H4 agonist,in combination with gemcitabine in a pancreatic cancer cell line.METHODS:Three kinds of human pancreatic cancer cell lines(Panc-1,MiaPaCa-2,and AsPC-1)were used in this study.Expression of H3 and H4 receptors in pancreatic cancer cells was identified with Western blotting.Effects of clobenpropit on cell proliferation,migration and apoptosis were evaluated.Alteration of epithelial and mesenchymal markers after administration of clobenpropit was analyzed.An in vivo study with a Panc-1xenograft mouse model was also performed.RESULTS:H4 receptors were present as 2 subunits in human pancreatic cancer cells,while there was no expression of H3 receptor.Clobenpropit inhibited cell migration and increased apoptosis of pancreatic cancer cells in combination with gemcitabine.Clobenpropit up-regulated E-cadherin,but down-regulated vimentin and matrix metalloproteinase 9 in real-time polymerase chain reaction.Also,clobenpropit inhibited tumor growth(gemcitabine 294±46 mg vs combination 154±54 mg,P=0.02)and enhanced apoptosis in combination with gemcitabine(control 2.5%,gemcitabine25.8%,clobenpropit 9.7%and combination 40.9%,P=0.001)by up-regulation of E-cadherin and downregulation of Zeb1 in Panc-1 xenograft mouse.CONCLUSION:Clobenpropit enhanced the anti-tumor effect of gemcitabine in pancreatic cancer cells through inhibition of the epithelial-mesenchymal transition process. | Woo Hyun Paik Ji Kon Ryu Kyoung-Sin Jeong Jin Myung Park Byeong Jun Song Sang Hyub Lee Yong-Tae Kim Yong Bum Yoon | 2014 | World Journal of Gastroenterology2014，20，26： | 4 |
| 11 | Clinical Outcomes of Two‐Week Sequential and Concomitant Therapies for Helicobacter pylori Eradication: A Randomized Pilot Study显示文摘 | Ji Hyun Lim Dong Ho Lee Chiun Choi Seong Tae Lee Nayoung Kim Sook Hyang Jeong Jin Wook Kim Jin Hyeok Hwang Young Soo Park Sang Hyub Lee Cheol Min Shin Hyun Jin Jo Eun Sun Jang In sung Song Hyun Chae Jung | 2013 | Helicobacter2013，，3： | 4 |
| 12 | Effect of external beam radiotherapy on patency of uncovered metallic stents in patients with inoperable bile duct cancer显示文摘BACKGROUND: Although biliary decompression with metallic stenting is the preferred treatment for inoperable bile duct cancer(BDC), maintenance of patency is still unsatisfactory.We tried to assess the effectiveness and safety of external beam radiotherapy(EBRT) for prolonging stent patency in patients having uncovered metallic stents.METHOD: We retrospectively reviewed 50 patients who received endoscopic stenting, of whom 18 received EBRT(RT group) and 32 did not(non-RT group).RESULTS: No difference was found in baseline characteristics between the two groups. Although stent patency was longer in the RT group than that in the non-RT group(140.7±51.3 vs136.4±34.9 days, P=0.94), the difference was not statistically significant. There were a lower rate of stent occlusion(27.8% vs50.0% of patients, P=0.12) and a longer overall survival(420.1 ±73.2 vs 269.1±41.7 days, P=0.11) in the RT group than in the non-RT group, and the difference again was not statistically significant. The development of adverse reactions did not differ(55.6% vs 53.1% of patients, P=0.91). There was no serious adverse reaction in both groups(P=0.99).CONCLUSIONS: EBRT did not significantly improve stent patency in patients with inoperable BDC having uncovered metallic stents. However, EBRT was safe. Future trials withrefined protocols for better efficacy are expected. | Jun Kyu Lee Won Kwon Kwack Sang Hyub Lee Jin Hee Jung Jae Hyun Kwon In Woong Han Jin Ho Lee | 2014 | Hepatobiliary & Pancreatic Diseases International2014，13，4： | 3 |
| 13 | Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus‐related advanced hepatocellular carcinoma显示文摘 | Hye Sun Shin Seung Up Kim Jun Yong Park Do Young Kim Kwang‐Hyub Han Chae Yoon Chon Oidov Baatarkhuu Sang Hoon Ahn | 2012 | Journal of Gastroenterology and Hepatology2012，，9： | 3 |
| 14 | Multicenter phase Ⅱ trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer显示文摘AIM To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine(GEM)-refractory unresectable pancreatic cancer(PC).METHODS This study was a prospective, multicenter, one-arm, open-label, phase Ⅱ trial. Patients with unresectable PC, who showed disease progression during GEMbased chemotherapy were enrolled. All patients were administered FOLFIRINOX with reduced irinotecan and oxaliplatin(RIO; irinotecan 120 mg/m^2 and oxaliplatin 60 mg/m^2), which was set according to the phase Ⅰ study of FOLFIRINOX. The objective response rate(ORR), disease control rate(DCR), progressionfree survival(PFS), overall survival(OS), adverse events were evaluated. Additionally, changes in quality of life(QoL) were assessed using a questionnaire on QoL.RESULTS Between August 2015 and May 2016, a total of 48 patients were enrolled. The median follow-up time was 259 d with a median of 8.5 cycles. The ORR and DCR were 18.8% and 62.5%, respectively, including one patient who showed complete remission. The median PFS was 5.8 mo [95% confidence interval(CI): 3.7-7.9] and median OS was 9.0 mo(95%CI: 6.4-11.6). Neutropenia(64.6%) was the most common grade 3-4 adverse event, followed by febrile neutropenia(16.7%). Although 14.6% of patients experienced grade 3 fatigue, most non-hematologic AEs were under grade 2. In the QoL analysis, the global health status score before treatment was not different from the score at the last visit after treatment(45.43 ± 22.88 vs 48.66 ± 24.14, P = 0.548).CONCLUSION FOLFIRINOX with RIO showed acceptable toxicity and promising efficacy for GEM-refractory unresectable PC. However, this treatment requires careful observation of treatment-related hematologic toxicities. | Moon Jae Chung Huapyong Kang Ho Gak Kim Jong Jin Hyun Jun Kyu Lee Kwang Hyuck Lee Myung Hwan Noh Dae Hwan Kang Sang Hyub Lee Seungmin Bang 无 | 2018 | World Journal of Gastrointestinal Oncology2018，10，12： | 3 |
| 15 | Pravastatin activates PPARα/PPARγexpression in the liver and gallbladder epithelium of hamsters显示文摘BACKGROUND:Our earlier study with cultured gallbladder epithelial cells demonstrated that statins(HMG-CoA reductase inhibitors)activate the expression of PPARαand PPARγ, consequently blocking the production of pro-inflmmatory cytokines.The present study used hamsters to investigate the effects of pavastatin on PPARα/PPARγexpression in the liver and gallbladder epithelium,and to determine whether pravastatin suppresses cholesterol crystal formation in the gallbladder. METHODS:A total of 40 Golden Syrian male hamsters(4 weeks old)were randomly assigned to four groups(basal diet control; basal diet+pavastatin;high cholesterol diet;high cholesterol diet+pravastatin).All hamsters were 11 weeks old at the end of the experiment.The liver,gallbladder and bile were harvested. Immunohistochemical staining and Western blotting for PPARαand PPARγwere performed in the liver and gallbladder. A drop of fresh bile was examined for cholesterol crystals under a microscope. RESULTS:In the gallbladder and liver of the hamsters, pravastatin activated the PPARαand PPARγexpression of gallbladder epithelial cells and hepatocytes,and particularly the response of PPARγwas much stronger than that of PPARα. Pravastatin suppressed the formation of cholesterol gallstones or crystals in the gallbladder. CONCLUSION:Pravastatin is an effective medication to activate PPARs(especially PPARγ)in the liver and the gallbladder epithelium of hamsters,and contributes to the prevention of gallstone formation. | Seok Ho Dong Jin Lee Dong Hee Koh Min Ho Choi Hyun Joo Jang Sea Hyub Kae | 2011 | Hepatobiliary & Pancreatic Diseases International2011，10，2： | 3 |
| 16 | Clinical features of 20 patients with curatively resected biliary neuroendocrine tumours显示文摘 | Jaihwan Kim Woo Jin Lee Sang Hyub Lee Kyoung Bun Lee Ji Kon Ryu Yong-Tae Kim Sun-Whe Kim Yong Bum Yoon Jin Hyeok Hwang Ho-Seong Han Sang Myung Woo Sang Jae Park | 2011 | Digestive and Liver Disease2011，，12： | 3 |
| 17 | Single-session Combined Therapy with Chemoembolization and Radiofrequency Ablation in Hepatocellular Carcinoma Less than or Equal to 5 cm: A Preliminary Study显示文摘 | Sung-Gwon Kang Chang Jin Yoon Sook-Hyang Jeong Jin Wook Kim Sang Hyub Lee Kyung Ho Lee Young Hoon Kim | 2009 | Journal of Vascular and Interventional Radiology2009，，12： | 2 |
| 18 | Recurrence and Prognostic Factors of Ampullary Carcinoma after Radical Resection: Comparison with Distal Extrahepatic Cholangiocarcinoma显示文摘 | Sang Myung Woo MD Ji Kon Ryu MD Sang Hyub Lee MD Ji Won Yoo MD Joo Kyung Park MD Yong-Tae Kim MD Jin-Young Jang MD Sun-Whe Kim MD Gyeong Hoon Kang MD Yong Bum Yoon MD | 2007 | Annals of Surgical Oncology2007，，11： | 2 |
| 19 | Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma显示文摘AIM:To evaluate the clinical characteristics of patients with Barcelona Clinic Liver Cancer(BCLC)stage 0 and A hepatocellular carcinoma(HCC)after transarterial chemoembolization(TACE).METHODS:Between January 2001 and September2011,129 patients with BCLC stage 0 and stage A HCC who underwent TACE were retrospectively enrolled.Patient characteristics,routine computed tomography and TACE findings,survival time and 1-,5-,and 10-year survival rates,risk factors for mortality,and survival rates according to the number of risk factors were assessed.RESULTS:The mean size of HCC tumors was 2.4±1.1 cm,and the mean number of TACE procedures performed was 2.5±2.1.The mean overall survival time and 1-,5-,and 10-year survival rates were 80.6±4.9 mo and 91%,63%and 49%,respectively.In the Cox regression analysis,a Child-Pugh score>5(P=0.005,OR=3.86),presence of arterio-venous shunt(P=0.032,OR=4.41),amount of lipiodol used(>7 mL;P=0.013,OR=3.51),and female gender(P=0.008,OR=3.47)were risk factors for mortality.The 1-,5-,and 10-year survival rates according to the number of risk factors present were 96%,87%and 87%(no risk factors),89%,65%,and 35%(1 risk factor),96%,48%and unavailable(2 risk factors),and 63%,17%,and 0%(3 risk factors),respectively(P<0.001).CONCLUSION:TACE may be used as curative-intent therapy in patients with BCLC stage 0 and stage A HCC.The Child-Pugh score,arterio-venous shunt,amount of lipiodol used,and gender were related to mortality after TACE. | Heung Cheol Kim Ki Tae Suk Dong Joon Kim Jai Hoon Yoon Yeon Soo Kim Gwang Ho Baik Jin Bong Kim Chang Hoon Kim Hotaik Sung Jong Young Choi Kwang Hyub Han Seung Ha Park | 2014 | World Journal of Gastroenterology2014，20，3： | 2 |
| 20 | Comparison of Hepatic Venous Pressure Gradient and Two Models of End-stage Liver Disease for Predicting the Survival in Patients With Decompensated Liver Cirrhosis显示文摘 | Ki Tae Suk Chang Hoon Kim Seung Ha Park Ho Taik Sung Jong Young Choi Kwang Hyub Han So Hyung Hong Dae Yong Kim Jai Hoon Yoon Yeon Soo Kim Gwang Ho Baik Jin Bong Kim Dong Joon Kim | 2012 | Journal of Clinical Gastroenterology2012，，10： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员